MCID: OVR042
MIFTS: 73

Ovarian Cancer malady

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer

About this section

Aliases & Descriptions for Ovarian Cancer:

Name: Ovarian Cancer 11 46 24 13 48 36 2
Ovarian Carcinoma 11 46 13 25 12 48 66
Ovarian Neoplasm 11 66
Ovary Neoplasm 11 25
Primary Malignant Neoplasm of Ovary 66
Ovarian Cancer, Susceptibility to 12
Malignant Neoplasm of Ovary 66
 
Epithelial Ovarian Cancer 66
Malignant Tumour of Ovary 11
Ovarian Epithelial Cancer 37
Malignant Ovarian Tumor 11
Primary Ovarian Cancer 11
Tumor of the Ovary 11
Ovarian Neoplasms 37

Classifications:



Summaries for Ovarian Cancer

About this section
NIH Rare Diseases:46 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. many people with early ovarian cancer have no signs or symptoms of the condition. when present, symptoms are often nonspecific and blamed on other, more common conditions. most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as brca1 or brca2 hereditary breast and ovarian cancer syndrome, lynch syndrome and peutz-jeghers syndrome) and are inherited in an autosomal dominant manner. the best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy). last updated: 3/30/2015

MalaCards based summary: Ovarian Cancer, also known as ovarian carcinoma, is related to ovarian cancer, somatic and breast cancer, and has symptoms including pelvic pain and pelvic pain. An important gene associated with Ovarian Cancer is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways are RHO GTPases activate IQGAPs and Bacterial invasion of epithelial cells. The drugs cyclophosphamide and cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the ovary, ovary and breast, and related mouse phenotypes are integument and reproductive system.

Disease Ontology:11 A female reproductive organ cancer that is located in the ovary.

Genetics Home Reference:24 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

MedlinePlus:36 The ovaries are part of the female reproductive system. they produce a woman's eggs and female hormones. each ovary is about the size and shape of an almond. cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. the sooner ovarian cancer is found and treated, the better your chance for recovery. but ovarian cancer is hard to detect early. women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. then it is hard to treat. symptoms may include a heavy feeling in the pelvis pain in the lower abdomen bleeding from the vagina weight gain or loss abnormal periods unexplained back pain that gets worse gas, nausea, vomiting, or loss of appetite to diagnose ovarian cancer, doctors do one or more tests. they include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. treatment is usually surgery followed by chemotherapy. nih: national cancer institute

CDC:2 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

Novus Biologicals:49 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

Wikipedia:69 Ovarian cancer is a cancer that forms in an ovary. It results in abnormal cells that have the ability to... more...

Related Diseases for Ovarian Cancer

About this section

Diseases in the Ovarian Cancer family:

Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 269)
idRelated DiseaseScoreTop Affiliating Genes
1ovarian cancer, somatic34.7AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
2breast cancer32.5AKT1, BARD1, BRCA1, BRCA2, CDH1, CTNNB1
3ovarian small cell carcinoma31.7CTNNB1, ERBB2, PIK3CA
4leiomyosarcoma31.1BRCA1, BRCA2, ERBB2
5serous cystadenocarcinoma31.1CDH1, ERBB2, MUC1
6familial breast cancer31.0BRCA1, BRCA2
7prostate cancer30.5AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
8hereditary breast ovarian cancer12.3
9breast-ovarian cancer, familial 412.1
10breast-ovarian cancer, familial 312.1
11brca1 hereditary breast and ovarian cancer syndrome12.1
12brca2 hereditary breast and ovarian cancer syndrome12.1
13breast-ovarian cancer, familial, 212.1
14breast-ovarian cancer, familial, 112.1
15brca1 and brca2 hereditary breast and ovarian cancer12.0
16childhood ovarian cancer12.0
17rad51c-related familial susceptibility to breast-ovarian cancer11.8
18rad51d-related familial susceptibility to breast-ovarian cancer11.8
19hereditary site-specific ovarian cancer syndrome11.8
20familiar ovarian carcinoma11.8
21cutaneous lupus erythematosus11.2BRCA1, BRCA2, ERBB2
22congenital pulmonary veins atresia or stenosis11.2BRCA1, BRCA2
23cervical serous adenocarcinoma11.2BRCA1, BRCA2, ERBB2
24rectum mucinous adenocarcinoma11.2BRCA1, BRCA2, ERBB2
25distal monosomy 9p11.2BRCA1, BRCA2, ERBB2, MUC16
26ductal carcinoma in situ11.2BRCA1, BRCA2, CDH1, ERBB2
27papillary adenofibroma11.2BRCA1, BRCA2, PIK3CA
28milker's nodule11.2BRCA1, BRCA2, CDH1, ERBB2
29internal auditory canal lipoma11.2BRCA1, BRCA2, ERBB2
30plethora of newborn11.2CDH1, CTNNB1, MUC1
31lipoma of the rectum11.2AKT1, BRCA1, BRCA2, PIK3CA
32breast malignant phyllodes tumor11.1CDH1, CTNNB1, ERBB2, MUC1
33breast papillary carcinoma11.1ERBB2, MUC1, PIK3CA
34spigelian hernia-cryptorchidism syndrome11.1CDH1, MUC16
35epilepsy with generalized tonic-clonic seizures11.1BRCA2, MSLN, MUC1
36plasmacytoma11.1AKT1, CDH1, CTNNB1, ERBB2
37bronchiolo-alveolar adenocarcinoma11.1BRCA2, ERBB2, MUC1
38pineal region meningioma11.1BARD1, BRCA1, BRCA2, ERBB2
39immune system cancer11.1BRCA1, ERBB2, MSLN
40spindle cell synovial sarcoma11.1BRCA1, BRCA2, MUC1
41zimmermann-laband syndrome 211.1AKT1, CDH1, ERBB2, PIK3CA
42visual cortex disease11.1BARD1, BRCA1, BRCA2, RAD51C
43gallbladder papillomatosis11.1AKT1, CDH1, CTNNB1, ERBB2, PIK3CA
44brittle bone syndrome lethal type11.1BARD1, BRCA1, BRCA2, ERBB2
45glomerulonephritis11.1CDH1, CTNNB1, ERBB2, PIK3CA
46mediastinal neurilemmoma11.1BRCA1, BRCA2, PIK3CA
47hartnup disorder11.1CDH1, ERBB2, MSLN, MUC1
48lung carcinoma in situ11.1BRCA1, BRCA2, ERBB2
49gastric cancer, somatic11.1CDH1, ERBB2, PIK3CA
50bronchopulmonary dysplasia11.1BRCA1, BRCA2

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to ovarian cancer

Symptoms for Ovarian Cancer

About this section

UMLS symptoms related to Ovarian Cancer:


pelvic pain

Drugs & Therapeutics for Ovarian Cancer

About this section

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
CEA-Scan16 Immunomedics April 1996
FDA Label: -
Disease/s that Drug Treats:colorectal cancer
Indications and Usage:16 -
DrugBank Targets:14 1. Carcinoembryonic antigen-related cell adhesion molecule 1
Mechanism of Action:16 
Target: carcinoembryonic antigen (""CEA"")
Action: marks
FDA: -
2
Doxil16 42 DOXORUBICIN HYDROCHLORIDE Alza June 1999
FDA Label: Doxil
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:16 DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:14 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:16 
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
3
Ethyol16 AMIFOSTINE Alza December 8, 1995
FDA Label: Ethyol
Disease/s that Drug Treats:ovarian cancer
Indications and Usage:16 ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated withrepeated administration of cisplatin in patients with advanced ovarian cancer.ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patientsundergoing post-operative radiation treatment for head and neck cancer, where the radiationport includes a substantial portion of the parotid glands (see Clinical Studies).For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin basedchemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limiteddata on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings.ETHYOL should not be administered to patients in other settings where chemotherapy can produce asignificant survival benefit or cure, or in patients receiving definitive radiotherapy, except in thecontext of a clinical study (see WARNINGS).
DrugBank Targets:14 1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1;2. Alkaline phosphatase, placental-like
Mechanism of Action:16 
Target: -
Action: -
FDA: -
4
Hycamtin16 42 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/ May 1996
FDA Label: Hycamtin
Disease/s that Drug Treats:small cell lung cancer/ ovarian cancer
Indications and Usage:16 HYCAMTIN for injection is a topoisomerase inhibitor indicated for: metastatic carcinoma of the ovary after disease progression on or afterinitial or subsequent chemotherapy. (1.1) small cell lung cancer platinum-sensitive disease in patients whoprogressed after first-line chemotherapy. (1.2) combination therapy with cisplatin for Stage IV-B, recurrent, orpersistent carcinoma of the cervix which is not amenable to curativetreatment. (1.3)
DrugBank Targets:14 1. DNA topoisomerase 1;2. DNA topoisomerase I, mitochondrial;3. DNA
Mechanism of Action:16 
Target: topoisomerase I
Action: inhibitor
FDA: Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks.Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these singlestrandbreaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damageproduced during DNA synthesis, when replication enzymes interact with the ternary complexformed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repairthese double-strand breaks.
5
Iressa16 42 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:16 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced ormetastatic non-small cell lung cancer after failure of both platinum-based and docetaxelchemotherapies who are benefiting or have benefited from IRESSA.In light of positive survival data with other agents including another oral EGFR inhibitor, physiciansshould use other treatment options in advanced non-small cell lung cancer patient populations whohave received one or two prior chemotherapy regimens and are refractory or intolerant to their mostrecent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICALPHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate anincrease in survival have been unsuccessful. Specifically, results from a large placebo-controlledrandomized trial in patients with advanced NSCLC who progressed while receiving or within 90 daysof the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, didnot show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studiessection).Results from two large, controlled, randomized trials in first-line treatment of non-small cell lungcancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:14 1. Epidermal growth factor receptor
Mechanism of Action:16 
Target: EGFR tyrosine kinase and other tyrosine kinases
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinibinhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembranecell surface receptors, including the tyrosine kinases associated with the epidermal growth factorreceptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.No clinical studies have been performed that demonstrate a correlation between EGFR receptorexpression and response to gefitinib.
6
Lynparza16 42 OLAPARIB AstraZeneca December 2014
FDA Label: Lynparza
Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:16 Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14)
DrugBank Targets:14 1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:16 
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.
7
Iressa16 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:16 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. In light of positive survival data with other agents including another oral EGFR inhibitor, physicians should use other treatment options in advanced non-small cell lung cancer patient populations who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies section). Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:14 Epidermal growth factor receptor
Mechanism of Action:16 
Target: EGFR tyrosine kinase
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFR receptor expression and response to gefitinib.

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 411)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1167631703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
2
SibutraminePhase 432106650-56-05210
Synonyms:
1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
106650-56-0
84485-00-7 (hydrochloride)
AC-15773
AC1L1JUC
AKOS004119970
BSPBio_002737
BTS-54524
Butramin
Butramin (TN)
C07247
C17H26ClN
CHEMBL1419
CID5210
CPD000238156
D08513
DB01105
DEA No. 1675
FT-0082832
HMS2052P05
HMS2090N17
I05-0006
KBio2_002508
KBio2_005076
KBio2_007644
KBio3_001957
KBioGR_001653
 
KBioSS_002516
LS-172014
MLS001066619
MLS001401362
Medaria
Meridia
MolPort-002-507-758
N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl
NCGC00092357-02
Reductil
SAM001247105
SMR000238156
SPBio_001612
STK802066
STOCK4S-20116
Sibutramina
Sibutramina [Spanish]
Sibutramine (INN)
Sibutramine [INN:BAN]
Sibutraminum
Sibutraminum [Latin]
Spectrum2_001686
Spectrum3_001009
Spectrum4_001137
Spectrum5_001440
Spectrum_001961
TL8000239
UNII-WV5EC51866
sibutramine
3
RosiglitazonePhase 4220122320-73-477999
Synonyms:
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
122320-73-4
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
AC-3459
AC1L2U9N
Avandia
BRD-A97437073-001-02-3
BRD-A97437073-001-03-1
BRL49653
BSPBio_002693
Brl 49653
Brl-49653
C18H19N3O3S
CID77999
D08491
DB00412
Gaudil
Gaudil (TN)
HMS1922J11
HMS2094O13
HSDB 7555
I06-0141
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
KBio2_002183
KBio2_004751
KBio2_007319
KBio3_001913
 
KBioGR_001609
KBioSS_002183
LS-151340
MolPort-002-508-212
NCGC00095124-01
NCGC00095124-02
NCGC00095124-03
RGZ
RSG
Rosi
Rosigilitazone
Rosigliazone maleate
Rosiglitazon
Rosiglitazona
Rosiglitazone
Rosiglitazone (INN)
Rosiglitazone [INN:BAN]
Rosiglitazone maleate
Rosiglitazonum
Rosiglizole
S00306
SPBio_001142
SPECTRUM1504263
STOCK6S-23924
Spectrum2_001241
Spectrum3_000997
Spectrum4_001125
Spectrum5_001464
Spectrum_001703
TDZ 01
UNII-05V02F2KDG
[3H]rosiglitazone
rosiglitazona
rosiglitazone
rosiglitazone (Avandia)
rosiglitazonum
4
AcarbosePhase 48356180-94-0441184
Synonyms:
(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4S,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
(3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
1,4-DEOXY-4-((5-HYDROXYMETHYL-2,3,4-TRIHYDROXYCYCLOHEX-5,6-ENYL)AMINO)FRUCTOSE
1agm
1gah
1k1y
1lf9
1ukt
4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose
4,6-dideoxy-4-{[(1S,4S,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucose
56180-94-0
AC1L26GM
AC1L9APL
AC1L9G0J
AC1L9HYX
AC1NAU1X
AC1OCEJZ
ACI-(1-4)GLD-(1-4)GLC-(1-4)GLB
ACR
Acarbosa
Acarbosa [INN-Spanish]
Acarbose
Acarbose (JAN/USAN/INN)
Acarbose [USAN:BAN:INN:JAN]
Acarbosum
Acarbosum [INN-Latin]
Alpha-Acarbose
BAY-g 5421
BB_NC-1311
Bay g 5421
Bay-g-5421
Beta-Acarbose
C06802
C25H43NO18
CHEBI:2376
CHEBI:506767
CHEMBL1566
 
CHEMBL394434
CHEMBL569486
CID10627975
CID41774
CID441184
CID4432690
CID444254
CID445421
CPD000466376
D00216
DB00284
EINECS 260-030-7
Glucobay
Glucor
HMC-(1-4)AGL-(1-4)GLC-(1-4)GLC
HMS2051F03
HMS2093I22
LS-71702
MLS000759506
MLS001424056
MolPort-002-507-369
MolPort-003-844-373
NCGC00096061-01
NCGC00096061-02
NCGC00160515-01
O-4,6-Dideoxy-4-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose
O-4,6-Dideoxy-4-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1->4)-O-alpha-D-glucopyranosyl-(1->4)-D-glucose
O-4,6-Dideoxy-4-(((1S-(1alpha,4alpha,5beta,6alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose
Prandase
Prandase, Precose, Glucobay, Bay-g 5421, Acarbose
Precose
Precose (TN)
QPS
S1271_Selleck
SAM001246733
SMR000466376
SPECTRUM1505172
STK801930
UNII-T58MSI464G
acarbose
5MoxonidinePhase 41375438-57-24810
6
ZincPhase 4, Phase 021547440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
7
SerotoninPhase 4, Phase 3, Phase 2, Phase 1351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
8
HydrocortisonePhase 460250-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
9
Cyproterone acetatePhase 4, Phase 2, Phase 3, Phase 040427-51-0
Synonyms:
 
Cyproterone 17-O-acetate
10
CyproteronePhase 4, Phase 2, Phase 3, Phase 0402098-66-05284537
Synonyms:
(1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one
2098-66-0
6-Chlor-delta(6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron
6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron
6-Chlor-delta(sup 6)-1,2-alpha-methylen-17-alpha-hydroxyprogesteron [German]
6-chloro-17-hydroxy-1beta,2beta-dihydro-3'H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione
AC-6213
AC1L1EZB
AC1L27WO
Apo-cyproterone
BAY 94-8367
BAY94-8367
BSPBio_003462
C22H27ClO3
CHEBI:50742
CHEMBL142130
CID10044976
CID16417
CID3015
CID5284537
CID5702275
Ciproterona
Ciproterona Servycal
Ciproterona Servycal (TN)
Ciproterona [INN-Spanish]
Ciproterone
Ciproterone [DCIT]
CyPat
Cyproteron
Cyproterone (INN)
Cyproterone [INN:BAN]
 
Cyproterone acetate
Cyproteronum
Cyproteronum [INN-Latin]
D07766
DB04839
DivK1c_000786
Gen-Cyproterone
HMS1922K16
HMS502H08
IDI1_000786
KBio1_000786
KBio2_002052
KBio2_004620
KBio2_007188
KBio3_002966
KBioGR_001485
KBioSS_002052
LS-58798
MolPort-003-981-177
MolPort-005-932-862
NCGC00178048-01
NINDS_000786
Novo-cyproterone
SH 80881
SPBio_001594
SPECTRUM1503921
Spectrum2_001597
Spectrum3_001901
Spectrum4_000853
Spectrum5_001362
Spectrum_001572
UNII-E61Q31EK2F
cyproterone
11
CarboplatinPhase 4, Phase 3, Phase 2, Phase 1, Phase 0194241575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
12
EpinephrinePhase 4, Phase 388651-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
13
LiraglutidePhase 4293204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
14vitamin dPhase 4, Phase 3, Phase 2, Phase 11607
15
EtoricoxibPhase 490202409-33-4123619
Synonyms:
202409-33-4
5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine
5-chloro-2-(6-Methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
5-chloro-6'-Methyl-3-(P-(methylsulfonyl)phenyl)-2,3'-bipyridine
5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
5CH
AC1L3WZM
Algix
Arcoxia
C11718
C422649
CHEBI:106706
CHEBI:6339
CHEMBL416146
CID123619
D03710
DB01628
DB07166
ETORICOXIB
 
Etoricoxib
Etoricoxib (USAN/INN)
Etoricoxib [USAN:INN:BAN]
Etoricoxibe
Etoricoxibum
FT-0082494
HMS2090A05
L-791456
L001141
L791456
LS-181802
MK 0663
MK 663
MK-0663
MK-663
Merck Sharp & Dohme brand of etoricoxib
MolPort-003-847-339
NCGC00164578-01
Nucoxia
Tauxib
UNII-WRX4NFY03R
ZINC00579472
16
AlogliptinPhase 457850649-61-511450633
Synonyms:
2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile
850649-61-5
Alogliptin
Alogliptina
Alogliptine
 
Alogliptinum
CHEMBL376359
CID11450633
MolPort-005-933-065
SYR-322
UNII-JHC049LO86
17
PioglitazonePhase 4, Phase 0428111025-46-84829
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
AD 4833
AD-4833
Actos
Actos (TN)
Actost
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
 
HSDB 7322
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
Pioglitazone HCl
Pioglitazone Hydrochloride
Pioglitazone [BAN:INN]
Pioglitazone [Ban:Inn]
Pioglitazone [INN:BAN]
Pioglitazonum
Pioglitazonum [INN-Latin]
SPBio_001897
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
Spectrum_001623
U 72107
U 72107A
U-72107
U72,107A
UNII-X4OV71U42S
Zactos
nchembio790-comp10
pioglitazone (INN)
pioglitazone HCl
18dexetimidePhase 450021888-98-2
19
CitalopramPhase 450059729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
20
TolbutamidePhase 42264-77-75505
Synonyms:
1-Butyl-3-(4-methylphenylsulfonyl)urea
1-Butyl-3-(P-methylphenylsulfonyl)urea
1-Butyl-3-(P-tolylsulfonyl)urea
1-Butyl-3-(p-methylphenylsulfonyl)urea
1-Butyl-3-(p-tolylsulfonyl)urea
1-Butyl-3-(para-tolylsulfonyl) urea
1-Butyl-3-tosylurea
1-P-Toluenesulfonyl-3-butylurea
1-butyl-3-(4-methylphenyl)sulfonylurea
1-p-Toluenesulfonyl-3-butylurea
100735-34-0
3-(P-Tolyl-4-sulfonyl)-1-butylurea
3-(p-Tolyl-4-sulfonyl)-1-butylurea
3-(p-tolylsulfonyl)-1-butylurea
3-[p-Tolyl-4-sulfonyl]-1-butylurea
46968_FLUKA
46968_RIEDEL
64-77-7
AB00052110
AB1004876
AC-12490
AC1L1KHP
AC1Q2X3T
Aglicid
Apo-Tolbutamide
Apotex Brand of Tolbutamide
Arcosal
Arkozal
Artosin
Artozin
Aventis Brand of Tolbutamide
BIDD:PXR0179
BIM-0051121.0001
BPBio1_000131
BRD-K85119730-001-06-5
BRN 1984428
BSPBio_000119
BSPBio_001507
BSPBio_002078
Beglucin
Berlin Chemie Brand of Tolbutamide
Berlin-Chemie Brand of Tolbutamide
Bio1_000206
Bio1_000695
Bio1_001184
Bio2_000227
Bio2_000707
Butamid
Butamide
Butamide Brand of Tolbutamide
Butamidum
C07148
C12H18N2O3S
CAS-64-77-7
CBiol_001920
CCRIS 592
CHEBI:27999
CHEMBL782
CID5505
CPD000058363
D 860
D00380
D014044
DB01124
Diaben
Diabesan
Diabetamid
Diabetol
Diabuton
Diasulfon
Diaval
Dirastan
DivK1c_000341
Dolipol
Drabet
EINECS 200-594-3
EU-0101154
Glyconon
HLS 831
HMS1361L09
HMS1568F21
HMS1791L09
HMS1989L09
HMS2089C17
HMS2092M21
HMS501B03
HSDB 3393
Hoechst Brand of Tolbutamide
IDI1_000341
IDI1_033977
Ipoglicone
KBio1_000341
KBio2_000227
KBio2_000927
KBio2_002275
KBio2_002795
KBio2_003495
KBio2_004843
KBio2_005363
KBio2_006063
KBio2_007411
KBio3_000453
KBio3_000454
KBio3_001578
KBio3_002755
KBioGR_000227
KBioGR_000795
KBioGR_002275
KBioSS_000227
KBioSS_000927
KBioSS_002276
 
LS-278
Lopac-T-0891
Lopac0_001154
MLS000028399
MLS001148399
MLS002152944
Mobenol
MolPort-001-783-540
N-(4-Methylbenzenesulfonyl)-N'-butylurea
N-(4-Methylbenzenesulfonyl)-n'-butylurea
N-(4-Methylphenylsulfonyl)-N'-butylurea
N-(4-Methylphenylsulfonyl)-n'-butylurea
N-(P-Methylbenzenesulfonyl)-n'-butylurea
N-(Sulfonyl-P-methylbenzene)-n'-N-butylurea
N-(p-Tolylsulfonyl)-N'-butylcarbamide
N-(p-tolylsulfonyl)-N'-n-butylurea
N-4-(Methylbenzolsulfonyl)-n-butylurea
N-4-Methylbenzolsulfonyl-N-butylurea
N-Butyl-N'-(4-methylphenylsulfonyl)urea
N-Butyl-N'-(p-tolylsulfonyl)urea
N-Butyl-N'-p-toluenesulfonylurea
N-Butyl-N'-toluene-p-sulfonylurea
N-Butyl-n'-(4-methylphenylsulfonyl)urea
N-Butyl-n'-P-toluenesulfonylurea
N-N-Butyl-n'-tosylurea
N-n-Butyl-N'-tosylurea
NCGC00015999-01
NCGC00015999-02
NCGC00015999-03
NCGC00015999-07
NCGC00015999-14
NCGC00022721-03
NCGC00022721-04
NCGC00022721-05
NCGC00022721-06
NCGC00022721-07
NCGC00022721-08
NCGC00022721-09
NCGC00022721-10
NCI-C01763
NCIOpen2_009592
NINDS_000341
NSC 23813
NSC23813
Novo-Butamide
Orabet
Oralin
Oramide
Orezan
Orinase
Orinase (TN)
Orinase (tn)
Orinase Diagnostic
Orinaz
Oterben
Pfizer Brand of Tolbutamide
Pramidex
Prestwick0_000190
Prestwick1_000190
Prestwick2_000190
Prestwick3_000190
Prestwick_471
R.A.N. Brand of Tolbutamide
Rastinon
Restinon
SAM002554936
SMR000058363
SPBio_001000
SPBio_002040
SPECTRUM1500581
Sk-tolbutamide
Spectrum2_001210
Spectrum3_000599
Spectrum4_000358
Spectrum5_001272
Spectrum_000447
T 0891
T0891_FLUKA
T0891_SIGMA
TL8000121
TOLBUTAMIDE USP
Tarasina
Tol-Tab
Tolbet
Tolbusal
Tolbutamid
Tolbutamid R.A.N.
Tolbutamida
Tolbutamida [INN-Spanish]
Tolbutamide
Tolbutamide (JP15/USP/INN)
Tolbutamide Aventis Brand
Tolbutamide Butamide Brand
Tolbutamide Hoechst Brand
Tolbutamide Pfizer Brand
Tolbutamide [INN:BAN:JAN]
Tolbutamidum
Tolbutamidum [INN-Latin]
Tolbutone
Toluina
Tolumid
Toluvan
Tolylsulfonylbutylurea
U 2043
UNII-982XCM1FOI
Valdecasas Brand of Tolbutamide
WLN: 4MVMSWR D1
Willbutamide
Yamanouchi Brand of Tolbutamide
ZINC01530703
cMAP_000008
tolbutamide
toluran
21
OlaparibPhase 4, Phase 3, Phase 2, Phase 1, Phase 0117763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
22taxanePhase 4, Phase 3, Phase 2, Phase 1335
23
TestosteronePhase 4, Phase 3, Phase 2, Phase 052458-22-06013
Synonyms:
(+)-testosterone
(+-)-8-iso-testosterone
(+-)-retrotestosterone
(+-)-testosterone
(17b)-17-hydroxy-androst-4-en-3-one
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
13-Iso-testosterone
17-Hydroxy-(17-beta)-androst-4-en-3-one
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
17-Hydroxy-D4-androsten-3-one
17-Hydroxy-androst-4-en-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17-beta-Hydroxyandrost-4-en-3-one
17?-Hydroxy-4-androsten-3-one
17a-Hydroxy-(13a)-androst-4-en-3-one
17a-Hydroxy-13a-androst-4-en-3-one
17a-Hydroxy-14b-androst-4-en-3-one
17a-Hydroxy-androst-4-en-3-one
17b-Hydroxy-(10a)-androst-4-en-3-one
17b-Hydroxy-(13a)-androst-4-en-3-one
17b-Hydroxy-(8a)-androst-4-en-3-one
17b-Hydroxy-(8a,10a)-androst-4-en-3-one
17b-Hydroxy-(9b)-androst-4-en-3-one
17b-Hydroxy-(9b,10a)-androst-4-en-3-one
17b-Hydroxy-13a-androst-4-en-3-one
17b-Hydroxy-8a-androst-4-en-3-one
17b-Hydroxy-D4-androsten-3-one
17b-Hydroxy-androst-4-en-3-on
17b-Hydroxy-androst-4-en-3-one
17b-Hydroxyandrost-4-en-3-one
17b-Hydroxyandrost-4-ene-3-one
17b-Testosterone
17b-hydroxy-4-androsten-3-one
17beta-Hydroxy-3-oxo-4-androstene
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17beta-hydroxy-4-androsten-3-one
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-Androsten-3-one-17b-ol
4-androsten-17β-ol-3-one
4-androstene-17beta-ol-3-one
46923_FLUKA
46923_RIEDEL
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
8-Iso-testosterone
9b,10a-Testosterone
9b-Testosterone
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
AndroGel
Androderm
Androderm (TN)
Androgel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17b-ol-3-one
Androst-4-en-17beta-ol-3-one
Androst-4-ene-17b-ol-3-one
Andrusol
Andryl 200
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
BIDD:ER0555
BIM-0061761.0001
Beta Testosterone
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
D4-Androsten-17b-ol-3-one
DB00624
Dea No. 4000
Delatest
Delatestryl
Depo-Testadiol
Depo-Testosterone
Depo-Testosterone Cypionate
Depotest
EINECS 200-370-5
Epitestosteron
Everone 200
Geno-Cristaux Gremy
Geno-cristaux Gremy
Geno-cristaux gremy
HMS2052N11
HSDB 3398
Halotensin
Homosteron
Homosterone
 
Intrinsa
LMST02020002
LS-148813
LibiGel
Libigel
Lumitestosteron
MLS000563091
MLS001032098
MLS001306401
MLS002174283
Malerone
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, Aquaspension Injection
Malogen, aquaspension injection
Mertestate
Metandren
Methyltestosterone
MolPort-002-506-901
NCGC00091018-01
NSC 9700
Neo-Hombreol F
Neo-Testis
Neo-testis
Neotestis
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine Androgenique
Percutacrine androgenique
Primotest
Primoteston
Rac-17b-hydroxy-(13a)androst-4-en-3-one
Rac-17b-hydroxy-(8a)-androst-4-en-3-one
Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
Rac-17b-hydroxy-androst-4-en-3-one
Relibra
Retrotestosterone
S00309
S2033_Selleck
SAM001246921
SMR000058344
SMR001261453
Scheinpharm Testone-Cyp
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolent
Testolin
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
Testosterone
Testosterone (JAN/USP)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testostérone
Testoviron
Testoviron Schering
Testoviron T
Testoxyl
Testred
Testred Cypionate 200
Testrin-P.A
Testro AQ
Testro Aq
Testrone
Testryl
Tostrelle
Tostrex
Trans-Testosterone
UNII-3XMK78S47O
Viatrel
Virilon
Virilon IM
Virormone
Virosterone
ZINC06500184
beta testosterone
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
testosterone
trans-Testosterone
24
MethyltestosteronePhase 4, Phase 3, Phase 2, Phase 052458-18-46010
Synonyms:
17(alpha)-Methyl-delta(4)-androsten-17(beta)-ol-3-one
17-Methyltestosterone
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17-methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-delta(4)-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-methyl-delta-androsten-17beta-ol-3-one
17alpha-methyltestosterone
 
17beta-Hydroxy-17-methylandrost-4-en-3-one
17α-methyl-Δ4-androsten-17β-ol-3-one
17α-methyltestosterone
4-Androstene-17alpha-methyl-17beta-ol-3-one
Android
Methyltestosterone
Methyltestosteronum
Metiltestosterona
NSC-9701
Testred
Virilon
25DienogestPhase 4, Phase 24065928-58-7
26
Testosterone enanthatePhase 4, Phase 3, Phase 2, Phase 0524315-37-79416
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn L.A.
Andropository
Androtardyl
Atlatest
DEA No. 4000
DePatestrye
Delatest
Delatestryl
Depo-Testro Med
Ditate
Durathate
Everone
 
Exten test
Malogen L.A.
Malogen L.A.200
Orquisteron-E
Primotestone
Reposo TMD
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosterone 17-enanthate
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone enantate
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
27Testosterone undecanoatePhase 4, Phase 3, Phase 2, Phase 0524
28
Tranexamic AcidPhase 42411197-18-85526
Synonyms:
08455_FLUKA
1197-17-7
1197-18-8
1ceb
3-14-00-00868 (Beilstein Handbook Reference)
4-(Aminomethyl)-Cyclohexanecarboxylic Acid
4-(Aminomethyl)cyclohexanecarboxylic acid
4-(aminomethyl)cyclohexane-1-carboxylic acid
857653_ALDRICH
A0236
AB00052260
AB1003647
AC-4687
AC1L1KJH
AC1Q50F3
AC1Q546D
AC1Q5U04
ALBB-006013
AMCA
AMCHA
AMH
AR-1F6595
Acide tranexamique
Acide tranexamique [INN-French]
Acido tranexamico
Acido tranexamico [INN-Spanish]
Acidum tranexamicum
Acidum tranexamicum [INN-Latin]
Amikapron
Amstat
Anvitoff
BAY 3517
BPBio1_000069
BRN 2207452
BSPBio_000061
BSPBio_002837
CAS-1197-18-8
CHEBI:48669
CHEMBL292500
CHEMBL877
CID5526
CL 65336
CL-65336
Carxamin
Cyclocapron
Cyklokapron
Cyklokapron (TN)
D01136
DB00302
DV 79
DV-79
DV79
DivK1c_000655
EINECS 214-818-2
Emorhalt
Exacyl
Frenolyse
HMS1568D03
HMS1921F08
HMS2092P03
HMS502A17
Hexapromin
Hexatron
I04-0993
IDI1_000655
KABI 2161
KBio1_000655
KBio2_001871
KBio2_004439
KBio2_007007
KBio3_002337
KBioGR_000511
 
KBioSS_001871
LS-56611
LS-56612
LT00159441
Mastop
MolPort-001-792-390
MolPort-002-512-008
NCGC00016569-01
NCGC00016569-02
NCGC00016569-03
NCGC00094944-01
NCGC00094944-02
NINDS_000655
NSC 291305
NSC291305
Oprea1_786414
Prestwick0_000171
Prestwick1_000171
Prestwick2_000171
Prestwick3_000171
Prestwick_476
RP 18,429
Rikavarin
Rikavarin (TN)
Rikavarin-S
SPBio_000689
SPBio_001982
SPECTRUM1502026
STK503668
STOCK1N-16183
Spectrum2_000655
Spectrum3_001189
Spectrum4_000046
Spectrum5_001258
Spectrum_001391
Spiramin
Tamcha
Tranex
Tranexamate
Tranexamic acid (JP15/USAN/INN)
Tranexamic acid [USAN:INN:BAN:JAN]
Tranexamic acid cis-form
Tranexamsaeure
Tranexan
Tranexmic acid
Tranhexamic acid
Trans AMCHA
Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
Trans-p-(Aminomethyl)cyclohexanecarboxylic
Transamin
Transamin (TN)
Transamlon
Trasamlon
UNII-6T84R30KC1
Ugurol
WLN: L6TJ AVQ D1Z -T
cis-4-(Aminomethyl)cyclohexanecarboxylic acid
cis-4-Aminomethylcyclohexane-1-carboxylic acid
cis-AMCHA
t-AMCHA
tranexamic acid
tranexmic acid
trans-1-Aminomethylcyclohexane-4-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester
trans-4-Aminomethylcyclohexane-1-carboxylic acid
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-Amcha
trans-Tranexamic acid
trans-p-(Aminomethyl)cyclohexanecarboxylic acid
29
Medroxyprogesterone acetatePhase 4, Phase 214071-58-9
Synonyms:
(6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
17-Acetoxy-6alpha-methylprogesterone
17-Acetoxy-6α-methylprogesterone
17alpha-Hydroxy-6alpha-methylprogesterone acetate
17α-hydroxy-6α-methylprogesterone acetate
6-alpha-Methyl-17-alpha-acetoxyprogesterone
6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate
6alpha-Methyl-17-acetoxy progesterone
 
6alpha-Methyl-17alpha-hydroxyprogesterone acetate
6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate
6α-Methyl-17-acetoxy progesterone
6α-Methyl-17α-hydroxyprogesterone acetate
MPA
Medroxyacetate progesterone
Medroxyprogesterone 17-acetate
Medroxyprogesterone acetate
Methylacetoxyprogesterone
Metigestrona
30
MedroxyprogesteronePhase 4, Phase 2140520-85-410631
Synonyms:
(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
(6alpha)-17-hydroxy-6-methylpregn-4-ene-3,20-dione
17 alpha Hydroxy 6 alpha Methylprogesterone
17 alpha-Hydroxy-6 alpha-Methylprogesterone
17-Hydroxy-6.alpha.-methylprogesterone
17-Hydroxy-6a-methylprogesterone
17-Hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione
17-Hydroxy-6alpha-methylprogesterone
17.alpha.-Hydroxy-6.alpha.-methylprogesterone
17alpha-Hydroxy-6alpha-methyl-4-pregnene-3,20-dione
17alpha-Hydroxy-6alpha-methylprogesterone
4-08-00-02211 (Beilstein Handbook Reference)
46411_FLUKA
46411_RIEDEL
520-85-4
6-Dihydromegestrol
6-alpha-Methyl-17-alpha-hydroxyprogesterone
6.alpha.-Methyl-17.alpha.-hydroxyprogesterone
6alpha-Methyl-17alpha-hydroxyprogesterone
6alpha-Methyl-4-pregnen-17alpha-ol-3,20-dione
6alpha-Methyl-5-pregnen-17alpha-ol-3,20-dione
AC-14528
AC1L1VM7
Adgyn Medro
Aragest
Aragest 5
Asconale
BRN 2510965
C07119
CBP-1011
CHEBI:6715
CHEMBL1390
CID10631
CPD000058769
Clinofem
Clinovir
Colirest
Cycrin
D008525
D08166
DB00603
DMPA
Depo-Clinovir
Depo-Prodasone
Depo-Progestin
Depo-Promone
Depo-Provera
Depo-Subq Provera 104
Depot-Medroxyprogesterone acetate
EINECS 208-298-6
Farlutal
Farlutal inyectable
Farlutal inyectable (TN)
Farlutin
G-Farlutal
Gestapuran
HMS2052A13
HSDB 3114
Hematrol
Hydroxymethylprogesterone
Hysron
 
Indivina
LMST02030176
LS-118713
Lunelle
Lutopolar
Lutoral
M6013_SIGMA
MAP
MLS000069571
MLS001076098
MPA Gyn 5
Med-Pro
Medroprogesterone Acetate
Medrossiprogesterone
Medrossiprogesterone [DCIT]
Medrossiprogesterone [Dcit]
Medroxiprogesterona
Medroxiprogesterona [INN-Spanish]
Medroxiprogesteronum
Medroxyprogesteron
Medroxyprogesteron acetate
Medroxyprogesterone (INN)
Medroxyprogesterone Acetate
Medroxyprogesterone Strakan Brand
Medroxyprogesterone [INN:BAN]
Medroxyprogesteronum
Medroxyprogesteronum [INN-Latin]
Meprate
Methylhydroxyprogesterone
Metigestrona
MolPort-005-934-866
NCGC00023064-04
NSC 27408
NSC27408
Nadigest
Nidaxin
Novo-Medrone
Oragest
Perlutex
Perlutex Leo
Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6-alpha)- (9CI)
Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)- (9CI)
Prodasone
Progestalfa
Progevera
Provera
Proverone
Ralovera
Repromap
Repromix
SAM001246906
SMR000058769
ST082267
Sirprogen
Sodelut G
Strakan Brand of Medroxyprogesterone
U 8840
UNII-HSU1C9YRES
Veramix
ZINC05763835
g-Farlutal
medroxyprogesterone
31
OrlistatPhase 4, Phase 25296829-58-23034010
Synonyms:
(-)-Tetrahydrolipstatin
1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate
111397-16-1
96829-58-2
AC-19012
AC1MHWQP
Alli
Alli, Xenical, Tetrahydrolipstatin, Orlistat
BIDD:GT0853
C055122
C29H53NO5
CHEMBL175247
CID3034010
CPD000466339
D04028
DB01083
FT-0082584
GlaxoSmithKline brand of orlistat
HMS2051I08
Hoffmann-La Roche brand of orlistat
KS-1183
L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
L-Leucine,N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
LS-178328
MLS000759448
MLS001423955
 
MLS002207022
MolPort-005-938-035
N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone
NCGC00165856-01
O4139_SIGMA
Orlipastat
Orlipastatum
Orlipastatum [INN-Latin]
Orlistat (USAN/INN)
Orlistat [USAN:INN]
R-212
Ro 18-0647/002
Ro 18-0647/008
Ro-18-0647
Roche brand of orlistat
S1629_Selleck
SAM001246637
SMR000466339
THLP
Tetrahydrolipstatin
UNII-95M8R751W8
Xenical
Xenical (TN)
[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
nchembio.129-comp24
orlistat
32
PaclitaxelPhase 4, Phase 3, Phase 2, Phase 1, Phase 0269133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
33
ganirelixPhase 4, Phase 3, Phase 063123246-29-7, 124904-93-425081094
Synonyms:
123246-29-7
124904-93-4
CHEBI:336376
CHEMBL1251
D08010
Ganirelix
Ganirelix (INN)
Ganirelix [INN:BAN]
 
Ganirelix acetate
Ganirelixum
Ganirelixum [INN-Latin]
LS-181948
LS-187280
Orgalutran
Orgalutran (TN)
RS-26306
UNII-IX503L9WN0
34DeslorelinPhase 4, Phase 2, Phase 3163
35
TamoxifenPhase 4, Phase 3, Phase 2, Phase 136810540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
36TRIPTORELIN PAMOATEPhase 4, Phase 3, Phase 2157
37
MethylprednisolonePhase 4, Phase 2, Phase 3111883-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
38
BevacizumabPhase 4, Phase 3, Phase 2, Phase 1, Phase 01938216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
39PREDNISOLONE ACETATEPhase 4, Phase 2, Phase 31118
40
PrednisolonePhase 4, Phase 2, Phase 3111850-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
41
LetrozolePhase 4, Phase 3, Phase 2, Phase 1, Phase 0368112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
42
ToremifenePhase 4, Phase 2, Phase 32689778-26-73005573
Synonyms:
(Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1)
2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC)
2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine
2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
89778-26-7
89778-27-8 (citrate (1:1))
98644-21-4
AC-1751
AC1MHJ33
Acapodene
BIDD:ER0222
BIDD:GT0211
BIDD:PXR0202
C08166
CCRIS 8745
CHEBI:9635
CHEMBL1655
CID3005573
D08620
DB00539
 
Estrimex
FC-1157a
Farestone
GTX-006 (Acapodene)
GTx 006
GTx-006
HMS2090B22
LS-7729
MolPort-002-508-208
NCGC00160530-01
STK626445
STOCK6S-27411
Toremifene (INN)
Toremifene Base
Toremifene Citrate (1:1)
Toremifene [INN:BAN]
Toremifeno
Toremifeno [Spanish]
Toremifenum
Toremifenum [Latin]
UNII-7NFE54O27T
Z-Toremifene
toremifene
{2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine
43CLOMIPHENEPhase 4, Phase 2, Phase 3, Phase 1, Phase 0161
44
Citric AcidPhase 4, Phase 3, Phase 2, Phase 1, Phase 0106377-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
45ProgestinsPhase 4, Phase 2, Phase 3, Phase 1, Phase 0525
46
ProgesteronePhase 4, Phase 3, Phase 2, Phase 1, Phase 051557-83-05994
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17a-Progesterone
17alpha-Progesterone
17alpha-progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
46665_FLUKA
46665_RIEDEL
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC-700
AC1L1LKF
AI3-51682
Agolutin
Akrolutin
BB_NC-0185
BHR-100
BIDD:ER0547
BIDD:PXR0094
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
Bio-luton
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
CPD000058345
Colprosterone
Corlutin
Corlutina
Corluvite
Corporin
Corpus Luteum Hormone
Corpus luteum hormone
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
DR-2011
Delalutin
Delta(4)-pregnene-3,20-dione
Duraprogen
EINECS 200-350-6
ETI-411
EU-0100895
Endometrin
Estima
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
HSDB 3389
Hormoflaveine
Hormoluton
Hydroxyprogesterone Caproate
Hydroxyprogesterone Caproic acid
LMST02030159
LS-234
Lingusorbs
Lipo-Lutin
Lipolutin
Lopac0_000895
Lucorteum
Lucorteum Sol
Lucorteum sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin M
Lutocyclin
Lutocyclin M
 
Lutocyclin m
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MPA
Membrettes
Methylpregnone
Micronized Progesterone
MolPort-001-794-643
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
NCI60_042166
NSC 64377
NSC 9704
NSC-9704
NSC64377
NSC9704
Nalutron
Natural Progesterone
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
PROGESTERONE
Percutacrine
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Prestwick_411
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, water-soluble
Progesterone-Water Soluble
Progesterone: HBC complex
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Progestérone
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
SR-01000000088
SR-01000000088-5
Spectrum5_002053
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
beta-Progesterone
bmse000482
component of Cyclogesterin
corpus luteum hormone
delta(4)-Pregnene-3,20-dione
delta(Sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta4-Pregnene-3,20-dione
luteohormone
nchembio.2007.53-comp14
47
EnclomiphenePhase 4, Phase 2, Phase 3, Phase 1, Phase 016115690-57-0
Synonyms:
 
Clomiphene trans-form
48
Hyaluronic acidPhase 44199004-61-953477741, 24759
Synonyms:
Hyaluronan
Hyaluronate
Hyaluronic acid
Hylartil
Hyruan Plus
Luronit
 
Macronan
Mucoitin
Nutra-HAF
Q 5AQ
Sepracoat
Sepragel Sinus
Sofast
Synvisc
49
AcetylcysteinePhase 4, Phase 2, Phase 3, Phase 1304616-91-112035
Synonyms:
(2R)-2-acetylamino-3-Sulfanylpropanoic acid
(R)-2-acetylamino-3-Mercaptopropanoic acid
(R)-Mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
 
Fluprowit
L-Acetylcysteine
L-alpha-acetamido-beta-Mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-ACETYL-L-cysteine
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
50
DanazolPhase 41517230-88-528417
Synonyms:
(17a)-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
(1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
(1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol
1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
1-Ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-Cyclopenta[7,8]phenanthro[3,2-D]isoxazol-1-ol
17 alpha-Pregna-2,4-dien-20-yno[2,3-D] isoxazol-17 beta-ol
17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol
17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}
17230-88-5
17a-Pregna-2,4-dien-20-yne-[2,3-D]isoxazole-17b-ol
17a-Pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol
17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
1H-Cyclopenta[7,8]phenanthro[3,2-D]isoxazole- pregna-2,4-dien-20-yno[2,3-D]isoxazol-17-ol deriv.
AC-6836
AC1L1FAD
AC1Q282K
AC1Q29FD
Alphapharm Brand of Danazol
Antigen Brand of Danazol
BPBio1_000100
BRD-K48970916-001-03-0
BSPBio_000090
Bonzol
CCRIS 6747
CHEBI:4315
CHEMBL1479
CID28417
CPD000058321
Chronogyn
Cyclomen
D00289
D003613
DB01406
Danatrol
Danazant
Danazol (JAN/USP/INN)
Danazol [USAN:BAN:INN:JAN]
Danazol-ratiopharm
Danazole
Danazolum
Danazolum [INN-Latin]
Danocrine
 
Danocrine (TN)
Danogen
Danokrin
Danol
Danoval
Danovaol
Danzol
EINECS 241-270-1
HMS1568E12
HMS2090A22
Kendrick Brand of Danazol
LS-118524
Ladogal
MLS001066617
MLS001306473
MolPort-002-513-504
NCGC00164400-01
NCGC00179665-01
NSC 270916
NSC270916
Norciden
Panacrine
Prestwick0_000105
Prestwick1_000105
Prestwick2_000105
Prestwick3_000105
Prestwick_150
SAM002564203
SMR000058321
SPBio_002029
STOCK1N-23495
Sanofi Brand of Danazol
Sanofi Synthelabo Brand of Danazol
Sanofi Winthrop Brand of Danazol
UNII-N29QWW3BUO
WIN 17,757
WIN 17757
WIN-17757
Win 17, 757
Winobanin
ZINC03881958
[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol
anatrol
danazol
ratiopharm Brand of Danazol

Interventional clinical trials:

(show top 50)    (show all 2657)
idNameStatusNCT IDPhase
1Tranexamic Acid in Surgery of Advanced Ovarian CancerCompletedNCT00740116Phase 4
2Tumor Gene Expression in Women With Ovarian CancerCompletedNCT00817479Phase 4
3A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)CompletedNCT00727961Phase 4
4Guilford Genomic Medicine Initiative (GGMI)CompletedNCT01372553Phase 4
5PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving ChemotherapyCompletedNCT02805166Phase 4
6Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot StudyCompletedNCT02562170Phase 4
7Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and VomitingCompletedNCT01432015Phase 4
8A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue TreatmentCompletedNCT00190697Phase 4
9A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With CancerCompletedNCT00277160Phase 4
10The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian CystCompletedNCT00713778Phase 4
11A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian ReserveCompletedNCT00746278Phase 4
12Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)CompletedNCT00805935Phase 4
13Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian SyndromeCompletedNCT01675843Phase 4
14Second-Line Treatments for Anovulatory Infertility in PCOS PatientsCompletedNCT00558077Phase 4
15Structured Exercise Training Program Versus Hypocaloric Hyperproteic Diet in Obese Anovulatory Infertile Patients With PCOSCompletedNCT00473538Phase 4
16Danazol Treatment in Endometriosis Women Before IVFCompletedNCT01779232Phase 4
17N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary SyndromeCompletedNCT02239107Phase 4
18Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose ToleranceCompletedNCT00667498Phase 4
19The Effect of Metformin on Different Hormones in PCOS PatientsCompletedNCT02568488Phase 4
20Oral Contraceptive and Cardiovascular Risk in PCOSCompletedNCT00593294Phase 4
21Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF CyclesCompletedNCT01233206Phase 4
22Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone TreatmentCompletedNCT01372904Phase 4
23Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian SyndromeCompletedNCT01540747Phase 4
24Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS)CompletedNCT01004068Phase 4
25Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOSCompletedNCT02352597Phase 4
26Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled StudyCompletedNCT01021579Phase 4
27Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound ParametersCompletedNCT01514942Phase 4
28The Role of Estrogen in Luteinizing Hormone Surge and OvulationCompletedNCT01999569Phase 4
29Pain Post Abdominal Laparoscopy Prevention With ArcoxiaCompletedNCT00565682Phase 4
30hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVFCompletedNCT01365936Phase 4
31Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue MorcellatorsCompletedNCT00743080Phase 4
32Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin ResistanceCompletedNCT01511822Phase 4
33Study of Mechanisms of Anovulation in Polycystic Ovary SyndromeCompletedNCT00492882Phase 4
34The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary SyndromeCompletedNCT02460380Phase 4
35Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary SyndromeCompletedNCT02789488Phase 4
36Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of ObesityCompletedNCT02909933Phase 4
37Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOSCompletedNCT02683226Phase 4
38Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary SyndromeCompletedNCT02483299Phase 4
39Trial With Metformin in Women With Polycystic Ovary SyndromeCompletedNCT02280057Phase 4
40PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary SyndromeCompletedNCT02187250Phase 4
41LIPT - Liraglutide in Polycystic Ovary SyndromeCompletedNCT02073929Phase 4
42PDE-4 Inhibitor Roflumilast and Polycystic Ovary SyndromeCompletedNCT02037672Phase 4
43The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOSCompletedNCT01961180Phase 4
44Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on MetforminCompletedNCT01911468Phase 4
45Polycystic Ovary Syndrome and LiraglutideCompletedNCT01899430Phase 4
46Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican WomenCompletedNCT01675310Phase 4
47Polycystic Ovary Syndrome - Improving OutcomesCompletedNCT01504321Phase 4
48Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on HyperandrogenismCompletedNCT01360996Phase 4
49Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)CompletedNCT01279512Phase 4
50Epicardial Adipose Tissue Thickness in Polycystic Ovary Syndrome (PCOS)CompletedNCT01258946Phase 4

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: ovarian neoplasms

Genetic Tests for Ovarian Cancer

About this section

Genetic tests related to Ovarian Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of Ovary25
2 Ovarian Cancer25
3 Ovarian Neoplasm25

Anatomical Context for Ovarian Cancer

About this section

MalaCards organs/tissues related to Ovarian Cancer:

34
Ovary, Breast, Lung, Testes, T cells, Bone, Prostate

FMA organs/tissues related to Ovarian Cancer:

17
The ovary

Animal Models for Ovarian Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Ovarian Cancer:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:001077110.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, DPH1
2MP:000538910.4AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
3MP:000538410.3AKT1, BARD1, BRCA1, BRCA2, CDH1, CTNNB1
4MP:000200610.2AKT1, BARD1, BRCA1, BRCA2, CDH1, CTNNB1
5MP:000538010.1AKT1, BARD1, BRCA1, BRCA2, CDH1, CTNNB1
6MP:000537910.1AKT1, BRCA1, BRCA2, CDH1, CTNNB1, EEF1A2
7MP:00107689.7AKT1, BARD1, BRCA1, BRCA2, CDH1, CTNNB1

Publications for Ovarian Cancer

About this section

Articles related to Ovarian Cancer:

(show top 50)    (show all 6012)
idTitleAuthorsYear
1
Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells. (25964101)
2015
2
Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. (25190018)
2014
3
Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78. (24756776)
2014
4
Lack of association between the COMT rs4680 polymorphism and ovarian cancer risk: evidence from a meta-analysis of 3,940 individuals. (25292091)
2014
5
The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer. (24503464)
2014
6
Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. (24659709)
2014
7
TCEA3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells. (23357533)
2013
8
PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. (23340297)
2013
9
Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer. (24007497)
2013
10
Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis. (22733497)
2012
11
Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. (22832979)
2012
12
Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. (22396544)
2012
13
Correlation of prostaglandin metabolizing enzymes and serum PGE2 levels with vitamin D receptor and serum 25(OH)2D3 levels in breast and ovarian cancer. (22213326)
2012
14
Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer. (22589409)
2012
15
The expression of I^-microseminoprotein but not CRISP3 is reduced in ovarian cancer and correlates to survival. (22993349)
2012
16
An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations. (20878485)
2011
17
The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. (21451362)
2011
18
Jagged1 expression regulated by Notch3 and Wnt/I^-catenin signaling pathways in ovarian cancer. (20953350)
2010
19
Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. (20118984)
2010
20
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. (20852632)
2010
21
Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer. (20437199)
2010
22
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. (19190154)
2009
23
Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. (19622337)
2009
24
Effect of Lewis y antigen on regulating gene expression of partial drug resistance associated proteins in human ovarian cancer cell line RMG-I-H]. (19771739)
2009
25
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. (19446547)
2009
26
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. (18566213)
2008
27
Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy. (17478446)
2007
28
Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases. (16740297)
2006
29
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. (17088436)
2006
30
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. (16801542)
2006
31
Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. (16461565)
2006
32
PIK3CA mutations in ovarian cancer. (16203798)
2005
33
Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. (14676209)
2004
34
Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. (12694652)
2003
35
Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. (12969782)
2003
36
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. (14651845)
2003
37
Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. (12404104)
2002
38
Relationship between the expression of connexin 43 and bystander effect of suicide gene therapy in ovarian cancer]. (11769669)
2001
39
Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. (11103784)
2000
40
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. (10702246)
2000
41
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. (10473101)
1999
42
Transforming growth factor-beta and nitrates in epithelial ovarian cancer. (10689548)
1999
43
Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer. (10475127)
1999
44
Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. (9475194)
1998
45
Screening for ESR mutations in breast and ovarian cancer patients. (9195227)
1997
46
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. (8988179)
1997
47
A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. (8751547)
1996
48
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. (8644702)
1996
49
Inherited breast and ovarian cancer. (8541881)
1995
50
The human insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer. (7507078)
1993

Variations for Ovarian Cancer

About this section

Clinvar genetic disease variations for Ovarian Cancer:

5
id Gene Variation Type Significance SNP ID Assembly Location
1PIK3CANM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
2PIK3CANM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
3BRCA1NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter)single nucleotide variantPathogenicrs80356898GRCh37Chr 17, 41245861: 41245861
4BRCA2NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter)single nucleotide variantPathogenicrs41293497GRCh37Chr 13, 32914174: 32914174
5BRCA1NM_007294.3(BRCA1): c.5095C> T (p.Arg1699Trp)single nucleotide variantPathogenicrs55770810GRCh37Chr 17, 41215948: 41215948

Cosmic variations for Ovarian Cancer:

8
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM550KRASurinary tract,bladder,carcinoma,undifferentiated carcinomac.181C>Gp.Q61E0

Copy number variations for Ovarian Cancer from CNVD:

6 (show top 50)    (show all 8010)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1134131123549970DeletionAADACL3Ovarian cancer
2134141123549970DeletionAADACL4Ovarian cancer
3134151123549970DeletionACAP3Ovarian cancer
4134161123549970DeletionACOT7Ovarian cancer
5134171123549970DeletionACTL8Ovarian cancer
6134181123549970DeletionACTRT2Ovarian cancer
7134191123549970DeletionAGMATOvarian cancer
8134201123549970DeletionAGRNOvarian cancer
9134211123549970DeletionAGTRAPOvarian cancer
10134221123549970DeletionAJAP1Ovarian cancer
11134231123549970DeletionAKR7A2Ovarian cancer
12134241123549970DeletionAKR7A3Ovarian cancer
13134251123549970DeletionAKR7LOvarian cancer
14134261123549970DeletionALDH4A1Ovarian cancer
15134271123549970DeletionALPLOvarian cancer
16134281123549970DeletionANGPTL7Ovarian cancer
17134291123549970DeletionAPITD1Ovarian cancer
18134301123549970DeletionARHGEF10LOvarian cancer
19134311123549970DeletionARHGEF16Ovarian cancer
20134321123549970DeletionARHGEF19Ovarian cancer
21134331123549970DeletionATAD3AOvarian cancer
22134341123549970DeletionATAD3BOvarian cancer
23134351123549970DeletionATAD3COvarian cancer
24134361123549970DeletionATP13A2Ovarian cancer
25134371123549970DeletionAURKAIP1Ovarian cancer
26134381123549970DeletionB3GALT6Ovarian cancer
27134391123549970DeletionC1QAOvarian cancer
28134401123549970DeletionC1QBOvarian cancer
29134411123549970DeletionC1QCOvarian cancer
30134421123549970DeletionC1orf126Ovarian cancer
31134431123549970DeletionC1orf127Ovarian cancer
32134441123549970DeletionC1orf144Ovarian cancer
33134451123549970DeletionC1orf151Ovarian cancer
34134461123549970DeletionC1orf158Ovarian cancer
35134471123549970DeletionC1orf159Ovarian cancer
36134481123549970DeletionC1orf170Ovarian cancer
37134491123549970DeletionC1orf174Ovarian cancer
38134501123549970DeletionC1orf187Ovarian cancer
39134511123549970DeletionC1orf200Ovarian cancer
40134521123549970DeletionC1orf64Ovarian cancer
41134531123549970DeletionC1orf70Ovarian cancer
42134541123549970DeletionC1orf86Ovarian cancer
43134551123549970DeletionC1orf89Ovarian cancer
44134561123549970DeletionC1orf93Ovarian cancer
45134571123549970DeletionCA6Ovarian cancer
46134581123549970DeletionCALML6Ovarian cancer
47134591123549970DeletionCAMK2N1Ovarian cancer
48134601123549970DeletionCAMTA1Ovarian cancer
49134611123549970DeletionCAPZBOvarian cancer
50134621123549970DeletionCASP9Ovarian cancer

Expression for genes affiliated with Ovarian Cancer

About this section
Search GEO for disease gene expression data for Ovarian Cancer.

Pathways for genes affiliated with Ovarian Cancer

About this section

Pathways related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 32)
idSuper pathwaysScoreTop Affiliating Genes
110.4CDH1, CTNNB1
210.4CDH1, CTNNB1, PIK3CA
310.4CDH1, CTNNB1, PIK3CA
4
Show member pathways
10.4BRCA1, BRCA2, RAD51C
510.4AKT1, BRCA1, CTNNB1
610.4AKT1, BRCA1, CTNNB1
710.4CDH1, CTNNB1, ERBB2
8
Show member pathways
10.4AKT1, CTNNB1, PIK3CA
9
Show member pathways
10.4BARD1, BRCA1, BRCA2
10
Show member pathways
10.4AKT1, ERBB2, PIK3CA
1110.4AKT1, ERBB2, PIK3CA
1210.4AKT1, CDH1, PIK3CA
1310.4AKT1, CDH1, PIK3CA
14
Show member pathways
10.3AKT1, BRCA1, CTNNB1, PIK3CA
15
Show member pathways
10.3AKT1, BRCA2, ERBB2, PIK3CA
16
Show member pathways
10.3AKT1, CTNNB1, ERBB2, PIK3CA
17
Show member pathways
10.3AKT1, CTNNB1, ERBB2, PIK3CA
1810.3AKT1, CTNNB1, ERBB2, PIK3CA
1910.3AKT1, CDH1, CTNNB1, PIK3CA
2010.3AKT1, CDH1, ERBB2, PIK3CA
21
Show member pathways
10.3BARD1, BRCA1, BRCA2, RAD51C
22
Show member pathways
10.3BARD1, BRCA1, BRCA2, RAD51C
23
Show member pathways
10.3AKT1, BARD1, BRCA1, PIK3CA
2410.3CDH1, CTNNB1, MSLN, MUC1
25
Show member pathways
10.3AKT1, CDH1, CTNNB1, ERBB2, PIK3CA
26
Show member pathways
10.3AKT1, CDH1, CTNNB1, ERBB2, PIK3CA
2710.3AKT1, CDH1, CTNNB1, ERBB2, MUC1
2810.3AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, PIK3CA
2910.3AKT1, BRCA2, CDH1, CTNNB1, ERBB2, PIK3CA
30
Show member pathways
10.3AKT1, CDH1, CTNNB1, ERBB2, MUC1, PIK3CA
3110.3AKT1, BARD1, BRCA1, BRCA2, CDH1, CTNNB1
32
Show member pathways
10.2AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2

GO Terms for genes affiliated with Ovarian Cancer

About this section

Cellular components related to Ovarian Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1BRCA1-A complexGO:007053110.7BARD1, BRCA1
2BRCA1-BARD1 complexGO:003143610.7BARD1, BRCA1
3apical junction complexGO:004329610.4CDH1, CTNNB1
4flotillin complexGO:001660010.3CDH1, CTNNB1
5catenin complexGO:001634210.1CDH1, CTNNB1

Biological processes related to Ovarian Cancer according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1protein K6-linked ubiquitinationGO:008502011.0BARD1, BRCA1
2chromosome breakageGO:003105210.9BRCA1, BRCA2
3DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.9BRCA1, BRCA2, MUC1
4double-strand break repair via homologous recombinationGO:000072410.9BRCA1, BRCA2, RAD51C
5chordate embryonic developmentGO:004300910.9BRCA1, BRCA2
6regulation of phosphatidylinositol 3-kinase signalingGO:001406610.9AKT1, ERBB2, PIK3CA
7cellular response to indole-3-methanolGO:007168110.7BRCA1, CDH1, CTNNB1
8ERBB2 signaling pathwayGO:003812810.7AKT1, ERBB2, PIK3CA
9cellular response to growth factor stimulusGO:007136310.5AKT1, CTNNB1, ERBB2, URI1
10cellular response to DNA damage stimulusGO:000697410.4AKT1, BARD1, BRCA1, BRCA2
11strand displacementGO:000073210.4BARD1, BRCA1, BRCA2, RAD51C
12DNA synthesis involved in DNA repairGO:000073110.3BARD1, BRCA1, BRCA2, RAD51C
13cell proliferationGO:000828310.3AKT1, BRCA2, CTNNB1, DPH1, ERBB2

Molecular functions related to Ovarian Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GTPase activating protein bindingGO:003279411.1AKT1, CDH1
2protein bindingGO:00055159.8AKT1, BARD1, BRCA1, BRCA2, CDH1, CTNNB1

Sources for Ovarian Cancer

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet